VivoSim Labs (VIVS) Operating Expenses (2010 - 2026)
VivoSim Labs (VIVS) posted quarterly Operating Expenses of $3.2 million for Q1 2026, up 0.69% year-over-year from $3.2 million in Q1 2025, and up 16.25% quarter-over-quarter from $2.8 million in Q4 2025.
VivoSim Labs (VIVS) Operating Expenses (2010 - 2026) Analysis & Trends
VivoSim Labs' Operating Expenses history runs 17 years deep, the most recent figure standing at $3.2 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 0.69% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $11.6 million (down 8.95% YoY), while the FY2026 annual figure was $11.6 million, down 8.95% from the prior year.
- Operating Expenses for Q1 2026 stood at $3.2 million, up from $2.8 million in the prior quarter.
- The five-year high for Operating Expenses was $7.9 million in Q1 2023, with the low at $2.6 million in Q3 2024.
- The 5-year median for Operating Expenses is $3.4 million (2022), against an average of $3.6 million.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses jumped 132.67% in 2023, then plunged 60.65% in 2024.
- VivoSim Labs' Operating Expenses stood at $3.5 million in 2022, then rose by 5.59% to $3.7 million in 2023, then fell by 5.24% to $3.5 million in 2024, then declined by 20.5% to $2.8 million in 2025, then rose by 16.25% to $3.2 million in 2026.
- Business Quant data shows VIVS's Operating Expenses at $3.2 million in Q1 2026, $2.8 million in Q4 2025, and $2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | 2.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.78 Mn |
| Mar 31, 2026 | 3.23 Mn |
| Dec 31, 2025 | 2.78 Mn |
| Sep 30, 2025 | 2.66 Mn |
| Jun 30, 2025 | 2.95 Mn |
| Mar 31, 2025 | 3.21 Mn |
| Dec 31, 2024 | 3.49 Mn |
| Sep 30, 2024 | 2.64 Mn |
| Jun 30, 2024 | 3.43 Mn |
| Mar 31, 2024 | 3.13 Mn |
| Dec 31, 2023 | 3.69 Mn |
| Sep 30, 2023 | 4.12 Mn |
| Jun 30, 2023 | 4.27 Mn |
| Mar 31, 2023 | 7.94 Mn |
| Dec 31, 2022 | 3.49 Mn |
| Sep 30, 2022 | 3.43 Mn |
| Jun 30, 2022 | 3.24 Mn |
| Mar 31, 2022 | 3.41 Mn |
| Dec 31, 2021 | 3.50 Mn |
| Sep 30, 2021 | 3.51 Mn |